koto_feja/E+ by way of Getty Photos
- Coya Therapeutics (NASDAQ:COYA) reported constructive interim results from an open-label study testing a mixture of low-dose IL-2 and CTLA4-Ig for the remedy of frontotemporal dementia.
- Within the interim results of the primary 5 sufferers, the remedy led to a major and
Source link
#Coya #Therapeutics #reports #promising #interim #results #dementia #study
